Definition/General
Introduction:
Fibrocystic changes are the most common benign breast condition
It is a general term for a collection of non-cancerous breast changes, including cysts, fibrosis, and adenosis
It is considered a normal variation of breast tissue.
Origin:
It is thought to be related to the hormonal fluctuations of the menstrual cycle.
Classification:
Fibrocystic changes are classified as non-proliferative, proliferative without atypia, or proliferative with atypia
The risk of subsequent breast cancer depends on this classification.
Epidemiology:
It is extremely common, affecting up to 60% of women, typically between the ages of 20 and 50.
Clinical Features
Presentation:
Presents as breast pain (mastalgia), lumpiness, and tenderness, which often fluctuate with the menstrual cycle.
Symptoms:
Cyclical breast pain and tenderness are the most common symptoms
Palpable lumps are often multiple and bilateral.
Risk Factors:
Hormonal factors play a key role.
Screening:
Mammography can show cysts, densities, and calcifications
Ultrasound is useful for distinguishing cysts from solid masses.
Master Fibrocystic Changes Pathology with RxDx
Access 100+ pathology videos and expert guidance with the RxDx app
Gross Description
Appearance:
The breast tissue is dense and fibrous, with multiple cysts of varying sizes
The cysts are often blue-domed and contain serous fluid.
Characteristics:
The tissue is rubbery and nodular.
Size Location:
Can involve the entire breast, but is often more prominent in the upper outer quadrants.
Multifocality:
Typically multifocal and bilateral.
Microscopic Description
Histological Features:
The key features are cysts, fibrosis, and adenosis
Cysts are dilated TDLUs
Fibrosis is an increase in the stromal fibrous tissue
Adenosis is an increase in the number of acini per lobule.
Cellular Characteristics:
The epithelial lining of the cysts is often flattened or shows apocrine metaplasia
Proliferative changes like usual ductal hyperplasia can be present.
Architectural Patterns:
A combination of cystic change, stromal fibrosis, and adenosis is characteristic.
Grading Criteria:
This is a benign condition
The presence of hyperplasia with atypia (ADH, ALH) is the most important prognostic factor.
Immunohistochemistry
Positive Markers:
Not typically required for diagnosis.
Negative Markers:
Not typically required for diagnosis.
Diagnostic Utility:
IHC is not used for the diagnosis of fibrocystic changes, but may be used to characterize associated proliferative lesions.
Molecular Subtypes:
Molecular subtyping is not relevant for this benign condition.
Molecular/Genetic
Genetic Mutations:
This is a benign condition and is not associated with specific genetic mutations.
Molecular Markers:
No specific molecular markers are routinely used for diagnosis.
Prognostic Significance:
Non-proliferative fibrocystic changes are not associated with an increased risk of breast cancer
Proliferative changes without atypia (e.g., UDH, sclerosing adenosis) are associated with a small increased risk (1.5-2 fold)
Proliferative changes with atypia (ADH, ALH) are associated with a moderate increased risk (4-5 fold).
Therapeutic Targets:
Treatment is symptomatic, including pain relief and reassurance
Aspiration of large, painful cysts can be performed.
Differential Diagnosis
Similar Entities:
It is important to distinguish fibrocystic changes from atypical proliferative lesions and carcinoma.
Distinguishing Features:
The key is to carefully evaluate the epithelial proliferation for the presence of atypia.
Diagnostic Challenges:
The main challenge is to identify small foci of atypia or carcinoma within a background of extensive fibrocystic changes.
Rare Variants:
There are no specific rare variants.
Sample Pathology Report
Template Format
Sample Pathology Report
Complete Report: This is an example of how the final pathology report should be structured for this condition.
Specimen Information
[specimen type], measuring [size] cm in greatest dimension
Diagnosis
[diagnosis name]
Classification
Classification: [classification system] [grade/type]
Histological Features
Shows [architectural pattern] with [nuclear features] and [mitotic activity]
Size and Extent
Size: [X] cm, extent: [local/regional/metastatic]
Margins
Margins are [involved/uninvolved] with closest margin [X] mm
Lymphovascular Invasion
Lymphovascular invasion: [present/absent]
Lymph Node Status
Lymph nodes: [X] positive out of [X] examined
Special Studies
IHC: [marker]: [result]
Molecular: [test]: [result]
[other study]: [result]
Final Diagnosis
Final diagnosis: [complete diagnosis]